​

Monte Rosa Therapeutics Ownership | Who Owns Monte Rosa Therapeutics?

OverviewForecastRevenueFinancialsChartTranscripts

Monte Rosa Therapeutics Ownership Summary

Monte Rosa Therapeutics is owned by 75.64% institutional investors, 0.73% insiders, and 23.63% retail investors. Nea management company is the largest institutional shareholder, holding 9.36% of GLUE shares. US Small-Cap Growth II Equity Comp is the top mutual fund, with 4.74% of its assets in Monte Rosa Therapeutics shares.

GLUE Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockMonte Rosa Therapeutics75.64%0.73%23.63%
SectorHealthcare Stocks 486.50%11.08%-397.59%
IndustryBiotech Stocks 304.14%11.08%-215.23%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Nea management company7.69M9.36%$34.69M
Price t rowe associates inc /md/7.12M8.68%$49.39M
Bvf inc/il5.66M6.89%$25.53M
Versant venture management5.65M6.88%$25.49M
Fmr5.55M6.77%$38.51M
Baker bros. advisors lp4.92M5.98%$22.17M
Blackrock funding, inc. /de3.85M4.68%$17.35M
Avoro capital advisors3.73M4.53%$16.80M
Suvretta capital management3.36M4.09%$15.15M
Blackrock2.36M3.92%$8.83M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Versant venture management5.65M31.04%$25.49M
Nea management company7.69M2.61%$34.69M
Aisling capital management lp1.47M1.85%$6.64M
Bvf inc/il5.66M0.91%$25.53M
Suvretta capital management3.36M0.46%$15.15M
Alphabet1.46M0.31%$6.60M
Avoro capital advisors3.73M0.29%$16.80M
Parkwood708.00K0.29%$3.19M
Baker bros. advisors lp4.92M0.22%$22.17M
Stonepine capital management30.00K0.13%$135.30K

Top Buyers

HolderShares% AssetsChange
Suvretta capital management3.36M0.46%1.80M
Vanguard group3.16M0.00%622.13K
Price t rowe associates inc /md/7.12M0.01%515.50K
Fmr5.55M0.00%447.04K
Norges bank445.87K0.00%445.87K

Top Sellers

HolderShares% AssetsChange
Avoro capital advisors3.73M0.29%-920.55K
Vestal point capital, lp---425.00K
Readystate asset management lp---287.00K
Jump financial---154.84K
Ikarian capital---136.57K

New Positions

HolderShares% AssetsChangeValue
Norges bank445.87K0.00%445.87K$3.09M
Quest partners94.63K0.09%94.63K$656.75K
Mackenzie financial77.64K0.00%77.64K$350.13K
Ieq capital73.97K0.00%73.97K$333.63K
Xtx topco54.44K0.01%54.44K$245.52K

Sold Out

HolderChange
Nelson, van denburg & campbell wealth management group-6.00
Us bancorp \de\-26.00
Capital performance advisors llp-29.00
Parkside financial bank & trust-95.00
Srs capital advisors-95.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 20251167.41%62,164,3354.44%751.44%7570.45%18-60.87%
Mar 31, 20256-94.44%15,774,831-74.13%190.35%3-95.77%1-94.12%
Dec 31, 202455-34.52%25,603,232-48.56%310.85%40-25.93%4-66.67%
Sep 30, 2024849.09%49,773,7858.59%601.47%5414.89%12-
Jun 30, 2024767.04%45,836,35414.90%761.26%4762.07%12-47.83%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
US Small-Cap Growth II Equity Comp2.91M4.74%-312.26K
T. Rowe Price New Horizons2.91M4.74%-14.50K
Vanguard Total Stock Mkt Idx Inv1.88M3.05%-41.40K
HBM Healthcare Investments AG Ord1.41M2.29%-
iShares Russell 2000 ETF1.08M1.75%-20.48K
Fidelity Growth Compy Commingled Pl O970.82K1.58%-
T. Rowe Price Health Sciences947.44K1.54%-35.67K
T. Rowe Price New Horizons Tr-A902.11K1.47%14.92K
T. Rowe Price New Horizons Tr-Z887.19K1.44%1.28K
Fidelity Select Pharmaceuticals Port796.40K1.30%-

Recent Insider Transactions

DateNameRoleActivityValue
Jun 03, 2025Dunn Edmund Principal Accounting OfficerSell$9.17K
Mar 24, 2025Leo Chandra P.-Buy$58.38K
Oct 29, 2024Versant Venture Capital VI, L.P.-Sell$146.79K
Oct 28, 2024Versant Venture Capital VI, L.P.-Sell$869.24K
Oct 29, 2024Versant Venture Capital VI, L.P.-Sell$475.01K

Insider Transactions Trends

DateBuySell
2025 Q2-1
2025 Q11-
2024 Q4-3
2024 Q3-5
2024 Q2-1

GLUE Ownership FAQ

Who Owns Monte Rosa Therapeutics?

Monte Rosa Therapeutics shareholders are primarily institutional investors at 75.64%, followed by 0.73% insiders and 23.63% retail investors. The average institutional ownership in Monte Rosa Therapeutics's industry, Biotech Stocks , is 304.14%, which Monte Rosa Therapeutics falls below.

Who owns the most shares of Monte Rosa Therapeutics?

Monte Rosa Therapeutics’s largest shareholders are Nea management company (7.69M shares, 9.36%), Price t rowe associates inc /md/ (7.12M shares, 8.68%), and Bvf inc/il (5.66M shares, 6.89%). Together, they hold 24.92% of Monte Rosa Therapeutics’s total shares outstanding.

Does Blackrock own Monte Rosa Therapeutics?

Yes, BlackRock owns 3.92% of Monte Rosa Therapeutics, totaling 2.36M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 8.83M$. In the last quarter, BlackRock increased its holdings by 53.08K shares, a 2.30% change.

Who is Monte Rosa Therapeutics’s biggest shareholder by percentage of total assets invested?

Versant venture management is Monte Rosa Therapeutics’s biggest shareholder by percentage of total assets invested, with 31.04% of its assets in 5.65M Monte Rosa Therapeutics shares, valued at 25.49M$.

Who is the top mutual fund holder of Monte Rosa Therapeutics shares?

US Small-Cap Growth II Equity Comp is the top mutual fund holder of Monte Rosa Therapeutics shares, with 4.74% of its total shares outstanding invested in 2.91M Monte Rosa Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools